[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects

Who is this study for? Patients with known or suspected bacterial infection
What treatments are being studied? [18F]fluoropropyl-trimethoprim
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1

The purpose of this study is to study a radioactive tracer, a type of imaging drug that is injected into the body to see how it is taken up in sites of active infection using an imaging procedure called Positron Emission Tomography/Computed Tomography (PET/CT).

Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No

• At least 18 years of age

• Known or suspected bacterial infection, per clinical documentation of suspected infection (e.g. lab results, pathology results, physician progress notes, clinical symptoms of infection)

• Able to understand the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures

United States
University of Pennsylvania
Contact Information
Supritha R Dugyala, B.S.
Time Frame
Start Date: February 7, 2020
Estimated Completion Date: January 2025
Target number of participants: 20
Other: Biodistribution cohort
The Biodistribution cohort will include up to 5 patients who will undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution [18F]fluoropropyl-trimethoprim PET/CT scans over a period of approximately 4 hours.
Other: The Dynamic cohort
The Dynamic cohort will include up to 15 patients who will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans post injection of [18F]fluoropropyl-trimethoprim.
Related Therapeutic Areas
Leads: University of Pennsylvania

This content was sourced from clinicaltrials.gov

Similar Clinical Trials